{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=27", "query": { "intervention": "fludarabine", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 1453, "total_pages": 146, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T19:47:27.961Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07411599", "title": "Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial (\"Chip-CRC Trial\")", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Peritoneal Metastases", "Carcinomatosis" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "NK Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2026-04-20", "completion_date": "2030-11-15", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07411599" }, { "nct_id": "NCT00579111", "title": "Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic and Myeloproliferative Disorders", "Acute Myelogenous Leukemia", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia", "Multiple Myeloma", "Plasma Cell Dyscrasia", "Lymphoproliferative Disorders", "Hematologic Diseases" ], "interventions": [ { "name": "Campath", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Hematopoietic stem cell infusion", "type": "PROCEDURE" }, { "name": "FK-506", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 4, "start_date": "2007-06", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2016-05-04", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579111" }, { "nct_id": "NCT01993719", "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Young TIL", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 33, "start_date": "2013-12-12", "completion_date": "2022-07-06", "has_results": true, "last_update_posted_date": "2023-01-18", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01993719" }, { "nct_id": "NCT05618925", "title": "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin's Lymphoma Refractory/Relapsed" ], "interventions": [ { "name": "N803", "type": "DRUG" }, { "name": "CD19t-haNK suspension", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-08-22", "completion_date": "2027-03-15", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 2, "location_summary": "Newport Beach, California • Tyler, Texas", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05618925" }, { "nct_id": "NCT07172958", "title": "Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rhabdomyosarcoma", "Ewing Sarcoma", "Neuroblastoma", "Wilms Tumor" ], "interventions": [ { "name": "Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "23 Years", "sex": "ALL", "summary": "1 Year to 23 Years" }, "enrollment_count": 18, "start_date": "2026-01-27", "completion_date": "2044-12", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07172958" }, { "nct_id": "NCT01273181", "title": "MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Metastatic Renal Cancer", "Metastatic Melanoma" ], "interventions": [ { "name": "PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2010-12", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273181" }, { "nct_id": "NCT03570892", "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy", "type": "DRUG" }, { "name": "Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 330, "start_date": "2019-05-09", "completion_date": "2026-02-03", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 22, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03570892" }, { "nct_id": "NCT04310592", "title": "Natural Killer Cell (CYNK-001) Infusions in Adults with AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Leukemia, Myeloid", "Leukemia, Myeloid, Acute", "Neoplasms by Histologic Type", "Neoplasms", "Immunosuppressive Agents", "Immunologic Factors", "Physiological Effects of Drugs", "Alkylating Agents", "Antimetabolites, Antineoplastic", "Antiviral Agents", "Analgesics, Non-narcotic", "Anti-infective Agents", "Analgesics", "Peripheral Nervous System Agents", "Hematologic Diseases", "Hematologic Neoplasms", "Leukemia in Remission", "Relapsed Adult AML", "Refractory AML" ], "interventions": [ { "name": "CYNK-001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 27, "start_date": "2020-03-12", "completion_date": "2023-04-28", "has_results": false, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 10, "location_summary": "Denver, Colorado • Chicago, Illinois • Hackensack, New Jersey + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04310592" }, { "nct_id": "NCT06690281", "title": "A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Carcinoma", "Pancreatic Cancer", "Hepatocellular Cancer", "Cholangiocarcinoma", "Duodenal Cancer", "Colorectal Cancer", "Small Bowel Cancer", "Metastatic Cancers" ], "interventions": [ { "name": "KRAS TCR-Transduced PBL", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 0, "start_date": "2025-09-09", "completion_date": "2025-09-09", "has_results": false, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06690281" }, { "nct_id": "NCT05238792", "title": "Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Tumor-associated antigen-specific T cell (TAA-T)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "70 Years", "sex": "ALL", "summary": "1 Year to 70 Years" }, "enrollment_count": 24, "start_date": "2021-11-17", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-28T19:47:27.961Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05238792" } ] }